CASE REPORT: A PATIENT WITH LARGE CELL NEUROENDOCRINE CARCINOMA OF UNKNOWN ORIGIN ACHIEVED AN EXCELLENT RESPONSE TO TEMOZOLOMIDE TREATMENT AFTER FAILURE OF TWO PREVIOUS CHEMOTHERAPY REGIMEN
.
.
Abstract
Large-cell neuroendocrine carcinoma of unknown primary origin is a rare entity with limited data, primarily from retrospective analyses or case reports. We herein present the case of a 71-year-old female with stage IV disease and extensive nodal involvement. After limited success with Etoposide-Carboplatin and then FOLFIRI, the patient achieved a remarkable clinical and radiological response to Temozolomide. Through this case, we summarized key clinical, paraclinical, and treatment outcome data from the literature.
.
Keywords
Euroendocrine carcinoma, Cancer of unknown primary, Temozolomide.
- Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol. 2009;36(1):52-59. doi:10.1053/j.seminoncol.2008.10.003
- Evangelou G, Trontzas IP, Gkiozos I, et al. The Effectiveness of Atezolizumab in Metastatic Large Cell Neuroendocrine Carcinoma of the Lungs: Insights from the LANCE Pilot Study. Biomedicines. 2024;12(6):1161. doi:10.3390/biomedicines12061161
- Kobayashi N, Takeda Y, Okubo N, et al. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma. Cancer Sci. 2021;112(5):1936-1942. doi:10.1111/cas.14811
- McGarrah PW, Leventakos K, Hobday TJ, et al. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma. Pancreas. 2020;49(4):529-533. doi:10.1097/MPA.0000000000001529
- Qi Z, Tan H. Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis. Biosci Rep. 2020;40(3):BSR20194127. doi:10.1042/BSR20194127
- Travis WD. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin. 2014;24(3):257-266. doi:10.1016/j.thorsurg.2014.04.001
